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TNC % Recovery
Prior RCF 300g Implemented
RCF 1300g
Range 85-93 85-98
Median 88 90
Standard Deviation 3.13 3.99
RCF selection Result: TNC % Recovery RCF 700g RCF 100g RCF 1300g
Range 91-106 91-100 93-100
Median 95.5 98.5 97.0
Standard Deviation 4.22 2.62 2.41172
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Although CMV infection only rarely leads to direct infectious
mortality, and early CMV reactivationmay reduce relapse rates
inpatientswithmyeloidmalignancies, themanagementofCMV
by preemptive antiviralsmay itself induce toxicity andﬁnancial
burdenwhich need to be quantiﬁed to provide justiﬁcation for
antiviral cellular immunotherapy. In this study, we analyzed
CMV reactivation in 134 (72 males, 62 females) patients un-
dergoing allo-SCT at our institute between 2006 through 2012,
comparing outcomes and cost after viral reactivation based
upon the risk of CMV reactivation. 102 subjects were trans-
planted for malignant diseases; and 32 were transplanted for
non-malignant diseases. 81 subjects received CD34+ selected
myeloablative, 12 received UCBT, and 41 had T-replete non-
myeloablative transplant.Medianageat transplantwas40years
and themedian follow-up is 4.25 years.119 (88.8%) were at risk
for CMV by virtue of either the donor or recipient being sero-
positive prior to transplant. Of these, 90 (75.6%) had CMV
reactivation in the blood (>250 copies/ml by PCR) including 4
(3.4%) who had CMV organ disease (involving the GI¼3 ,
lung¼2, CNS¼1) and all received antivirals.Median time toﬁrst
CMV reactivation was 34 days (range: 8-105 days). 11% reac-
tivated before d14+ and 92% by d100+. For comparison, we
deﬁned two groups: "Antiviral group" consisting of the 90
subjects (reactivation and/or organ disease) and a “No therapy
group" consistingof 44 subjects (29 at risk subjectswhodid not
need antiviral treatment, and 15 who were not at risk). The
Antiviral group averaged 12.6 days of IV antiviral therapy and
13.9 additional days of hospitalization (P<0.02). We calculated
the additional cost for the Antiviral group to be between
$55,000 to $71,000 per patient.We also evaluated the impact of
CMV risk on overall survival and on NRM but found no statis-
ticallysigniﬁcant impact.However, inmultivariablemodelingof
NRM, CMV reactivation>250 copies/ml (OR¼3, P<0.048), total
duration of inpatient IV antiviral therapy (OR¼ 1.04 ,P<0.001),
type of transplant (T-deplete vs. T-replete) (OR¼4.65 ,P<0.017) ,
were found to be signiﬁcantly associated; the model excluded
age, sex, diagnosis (malignant vs. nonmalignant) and CMV risk
status.Our ﬁndings document that although direct infectious
mortality from CMV has been eliminated, there is a signiﬁcant
cost of therapy in terms of drug and inpatient hospitalization as
well as a strong associationwithNRM. Implications for antiviral
cellular therapy are that early administration even prior to day
14 is necessary to meaningfully impact reactivation and that
cost savings exceeding $25,000 are possible with even moder-
ate (50%) reduction in the rate of reactivation requiring antiviral
therapy.
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Background: Original Performance Qualiﬁcation on Sorvall
ST40R Centrifuge for plasma depletion on Hematopoietic
progenitor cell (HPC) product was set at 300g Revolution
Centrifugal Force (RCF) 10 minutes at 20C to achieve  80%
Total Nucleated Cell (TNC) recovery. Cellular Therapy Lab
(CTL) noticed the spundownproduct has unclear supernatant
plasma, loosely packed cellular sedimentationwith difﬁculty
for separation. CTL has decided to re-validate the process to
ﬁnd an optimal RCF for a clear & deﬁned separation between
plasma and Buffy coat, maintaining  80% TNC recovery.
Study Design and Methods: Researchperformed onpractice
recommendations and referencematerials lead to select three
variables of RCF: 700g, 1000g, and 1300g for this study. Ten
samples were collected from different sources: single donor
whole blood; pooled whole blood; pre HPC,Apheresis pe-
ripheral blood; HPC product and Donor Lymphocyte product.
Sample size varied from 21ml e 120ml. Each sample was
divided into three equal portions centrifuged for 10 minutes
at 20C at the selected RCF.White blood cell (WBC) countwas
tested by the Sysmex cell counter. Viability was tested with
Trypan Bluemethod. The following data and test results were
recorded for each portionpre andpost centrifugation: sample
volume, WBC, packed cell volume, plasma volume, Post
plasma WBC, calculated TNC, Viability%, TNC % recovery,
Clarity of spun sample, and Appearance of Buffy-coat. One
way analysis of Variance was run to assess the P value for
statistical signiﬁcant difference. Optimal RCF was selected
after this study. Validation of the selected RCFwas performed
on 5 HPC products from prior transplant recipients.
Result: The study found no statistically signiﬁcant difference
among the 3 RCF variables with P¼0.67. The difference be-
tween Pre & Post Viability was less than 3 % which indicates
minimal cell damage during centrifugation. Observation
found hazy plasma and loose Buffy Coat with 700g, clear and
deﬁned with 1000g and 1300g. CTL selected RCF 1300g for
plasma depletion. Validation study on 7 processes found post
TNC plasma range of 0.01-0.10% of pre TNC, difference in Pre
& Post Viability is 0-1%, ﬁve patients with successful absolute
NC and platelet engraftment. Results of retro study compared
to 7 random processes using prior RCF 300g found P¼ 0.352.Conclusion: The study found no signiﬁcant difference in TNC
% recovery using 700g, 1000g and1300g. There is deﬁned cell
